PHARMANIAGA BHD
KLSE (MYR): PHARMA (7081)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.365
Today's Change
-0.005 (1.35%)
Day's Change
0.365 - 0.37
Trading Volume
88,600
Financial
Market Cap
Market Cap
526 Million
NOSH
1,441 Million
Latest Quarter
Latest Quarter
30-Jun-2024 [#2]
Announcement Date
21-Aug-2024
Next Quarter
30-Sep-2024
Est. Ann. Date
29-Nov-2024
Est. Ann. Due Date
29-Nov-2024
QoQ | YoY
-89.09% | 42.63%
T4Q Result
Revenue | NP to SH
3,478,508.000 | -53,617.000
RPS | P/RPS
241.36 Cent | 0.15
EPS | P/E | EY
-3.72 Cent | -9.81 | -10.19%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
-0.19 | 0.00
QoQ | YoY
1.54% | 91.51%
NP Margin | ROE
-1.47% | 0.00%
F.Y. | Ann. Date
30-Jun-2024 | 21-Aug-2024
Latest Audited Result
Latest Audited Result
31-Dec-2023
Announcement Date
29-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
29-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Annual (Unaudited)
Revenue | NP to SH
3,404,481.000 | -77,452.000
RPS | P/RPS
236.22 Cent | 0.15
EPS | P/E | EY
-5.37 Cent | -6.79 | -14.72%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
-0.20 | 0.00
YoY
87.25%
NP Margin | ROE
-2.23% | 0.00%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Annualized Result
Revenue | NP to SH
3,606,430.000 | 56,886.000
RPS | P/RPS
250.23 Cent | 0.15
EPS | P/E | EY
3.94 Cent | 9.25 | 10.81%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-44.55% | 517.25%
NP Margin | ROE
1.67% | 0.00%
F.Y. | Ann. Date
30-Jun-2024 | 21-Aug-2024
Business Process
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Positive Profit Years | 2 / 4 | 50.00% | 5 / 8 | 62.50% |
| Continuous Quarters Of Positive Profit | 2 / 4 | 50.00% | 2 / 8 | 25.00% |
| Continuous Quarters Of Profit Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted EPS Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Dividend Years | 0 / 4 | 0.00% | 1 / 8 | 13.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | 0.00% | 0.26% | ||
| Average Net Profit Margin | -1.61% | -9.94% | ||
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Quarters Of Revenue Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Positive Profit Years | 2 / 5 | 40.00% | 7 / 10 | 70.00% |
| Continuous Quarters Of Positive Profit | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Profit Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Continuous Quarters Of Adjusted EPS Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Total Dividend Years | 4 / 5 | 80.00% | 9 / 10 | 90.00% |
| Continuous Quarters Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Average ROE | 0.41% | 6.29% | ||
| Average Net Profit Margin | -4.04% | -0.57% | ||
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 3,478,508 | 3,606,430 | 3,404,481 | 2,848,595 | 3,455,154 |
| NP to SH | -53,617 | 56,886 | -77,452 | -31,457 | -126,869 |
| Dividend | 0 | 0 | 0 | 48,015 | 39,519 |
| Adjusted EPS | -3.72 | 3.94 | -5.37 | -2.18 | -8.80 |
| Adjusted DPS | 0.00 | 0.00 | 0.00 | 3.33 | 2.74 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | -13.13% | -1.23% | 4.28% | -3.61% | -4.13% |
| NP to Owner | -89.09% | 42.63% | 517.25% | 120.87% | 103.27% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adjusted EPS | -89.33% | 39.64% | 516.15% | 120.41% | 103.20% |
| Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.17% | 0.68% | 22.11% | 5.93% | 4.38% | 26.60% | -3.02% | -1.47% | 19.51% |
| NP to Owner | 30.77% | 57.74% | -70.44% | 173.45% | 144.84% | 280.84% | 87.25% | 38.95% | -146.21% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adjusted EPS | 30.78% | 57.74% | -70.43% | 173.32% | 144.76% | 280.51% | 87.25% | 38.95% | -146.21% |
| Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Discussions
6 people like this. Showing 50 of 14,126 comments
this is not a problematic company, its the gahmen yg forced them to hsndle covid vaccine till over supply..when kovid gone..stuck with oversupply dose.. ask Kj ler. now, gahmen hv silently help to fix the problem. Nx Qr will be more prolific..high probability Revenue over 1b. Current price consider low already..good to enter. Down side minimum..upper side. 50 cents 👍
2024-07-05 19:05
Look at other pharma players, their shares are all above RM2. This is the reason I said Pharmaniaga is underrated and it should be priced about RM4 if they are managing it well like others.
2024-07-09 12:29
current management good already, managed to submit their restructuring plan early this year, you compare with other PN17 company, take yearssss to submit even the first plan. % months olready, and Bursa should give the approval anytime soon. I would expect this month.. BTW, Next QR should touch 1 billion revenue. Imagine how many people in Indonesia?? They just open news branch in Feb 2024.. next QR will be full 3 months (mac - June) sales.
" In the Indonesia segment, the revenue growth was due to the surge in demand for products of existing principals and additional sales generated from the opening of two
new branches in February 2024."
2024-07-09 13:53
it will keep moving up steadily until the next QR released, if the report is good it will goes up further above RM1, and how high it could goes higher depends on the consistency of their financial performance as well as dividend given.
2024-07-10 17:36
Good morning guys, would like to congrats those who bought pharma at 30+- cents, the huge profit is awaiting us.
2024-07-11 09:17
for those who still have bullets may consider to get a train ticket asap as the gap of the stock price as of now to it supposed to be is big. big potential stock for mid term good profit investment.
2024-07-11 09:22
either regulation plan approved by Bursa or 1 billion revenue will makes this counter fly towards at least 50 cents! .
2024-07-11 20:54
It will be keep going up for sure as the company is in good shape now and keep improving from varies aspects. Bear in mind pharma is essential and is must + Pharmaniaga is the sole appointed supplier of nation.
2024-07-15 17:59
anticipating Bursa announcement about its regulation plan. Once out, should prepare how to act ..
2024-07-16 01:05
patient.. next QR will produce revenue above 1 Billion.. and out from PN17 status!. Grab it while still below 50 cents.. end of year above 60 cents
2024-07-18 12:28
And the catalyst that is likely to change the fortunes of the company — a proposed renounceable rights issue with warrants as a sweetener to shareholders that is slated to raise up to RM354.6 million; and, more importantly, a proposed private placement to a third-party investor or investors that could raise gross proceeds of up to RM300 million — could happen soon. Both the rights issue and placement are part of a regularisation plan to get Pharmaniaga out of PN17 classification, but are likely to have a far-reaching impact if management’s plans pan out.
2024-07-21 15:12
got nothing to do with Biden drops from presidential race .. people over here still need pills and treatment. Pelaung to top up😅
2024-07-22 11:42
Is there a dateline set by BURSA for PN17 status to be removed? Anyone knows?
2024-08-01 08:16
Michael Kwok dari Kenanga ? 🤔
https://klse.i3investor.com/web/pricetarget/research/72061
2024-08-02 18:29
rare opportunity to grab at this level.. medical sector will not be affected by US burst.
2024-08-05 15:05
People still need treatments.. government continue with medical spending!. current price consider reasonable.. between 36 - 38 cents. In my opinion, medical sector will become safe heaven during this turmoil event
2024-08-05 15:15
OTHERS | https://www.klsescreener.com/v2/announcements/view/7963613
Omg resignation of auditors
1 month ago
*** All look well.
*** Timely announcement: E&Y.
*** Improving biz trends.
*** Should be hot upon PN17 exit!
1 month ago
I think market are just waiting for uplift of PN17. Look at Dpharma, already up so much. Soon will be us.
1 month ago
bursa so lazy, its been mora than 6 month, not reply ..PMx should bur$4 activities which always favour the speculators!! so lazy la..
1 month ago
Post a Comment
Featured Posts
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2024-11-19 16:40:00
EMA 5
10 Mins
SELL
2024-11-19 16:40:00
EMA 5
5 Mins
SELL
2024-11-19 16:35:00
ADX
5 Mins
SELL
2024-11-19 16:30:00
EMA 5
30 Mins
SELL
2024-11-19 16:00:00
EMA 5
10 Mins
BUY
Apps
Top Articles
1
2
BFM Podcast
3
BFM Podcast
5
BFM Podcast
6
BFM Podcast
7
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
AmirIffaan
Jadi, tukar pihak pengurusan? 😁
2024-06-25 22:31